Krystal Biotech, Inc. $KRYS Shares Sold by Capital World Investors

Capital World Investors trimmed its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 14.1% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 809,240 shares of the company’s stock after selling 133,009 shares during the period. Capital World Investors’ holdings in Krystal Biotech were worth $142,855,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Sound View Wealth Advisors Group LLC increased its holdings in shares of Krystal Biotech by 2.9% during the 3rd quarter. Sound View Wealth Advisors Group LLC now owns 2,003 shares of the company’s stock worth $354,000 after buying an additional 56 shares during the last quarter. Bessemer Group Inc. lifted its holdings in Krystal Biotech by 106.9% in the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after acquiring an additional 77 shares during the last quarter. Arizona State Retirement System grew its position in Krystal Biotech by 1.3% in the third quarter. Arizona State Retirement System now owns 6,397 shares of the company’s stock worth $1,129,000 after acquiring an additional 81 shares during the period. Main Management ETF Advisors LLC grew its position in Krystal Biotech by 1.7% in the second quarter. Main Management ETF Advisors LLC now owns 5,131 shares of the company’s stock worth $705,000 after acquiring an additional 84 shares during the period. Finally, M&T Bank Corp increased its stake in Krystal Biotech by 2.3% during the second quarter. M&T Bank Corp now owns 3,785 shares of the company’s stock worth $520,000 after acquiring an additional 85 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Insider Buying and Selling

In related news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $267.60, for a total value of $200,700.00. Following the completion of the transaction, the chief accounting officer directly owned 22,366 shares in the company, valued at approximately $5,985,141.60. This trade represents a 3.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $263.21, for a total value of $6,580,250.00. Following the transaction, the insider directly owned 1,403,155 shares of the company’s stock, valued at $369,324,427.55. The trade was a 1.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 129,164 shares of company stock valued at $34,538,578 in the last three months. 13.70% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $310.00 price target (up from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. The Goldman Sachs Group boosted their price objective on shares of Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a report on Friday, January 30th. TD Cowen reaffirmed a “buy” rating on shares of Krystal Biotech in a research report on Friday, January 9th. Jefferies Financial Group increased their target price on shares of Krystal Biotech from $310.00 to $371.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Finally, Citigroup lifted their price target on shares of Krystal Biotech from $336.00 to $371.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Nine research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $326.25.

Krystal Biotech Stock Down 2.3%

Shares of KRYS opened at $255.00 on Thursday. The company has a market cap of $7.45 billion, a P/E ratio of 37.23 and a beta of 0.49. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $298.30. The firm’s 50 day moving average price is $270.39 and its 200 day moving average price is $221.13.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Tuesday, February 17th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. The company had revenue of $107.11 million during the quarter, compared to analysts’ expectations of $105.30 million. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. Research analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.